企業概要
National Health Investors, Inc. is a self-managed real estate investment trust that specializes in sale-leaseback transactions, joint ventures, and mortgage and mezzanine financing focused on need-driven and discretionary senior housing and medical facility investments. The company operates within the Real Estate sector, specifically the REIT - Healthcare Facilities industry, which denotes its primary function of owning and managing income-generating properties dedicated to senior living and healthcare services. Its operational scale is defined by a market capitalization of $4.17B, annual revenue of $379.29M, and a workforce comprising 32 employees. These valuation and revenue figures indicate that the company holds a significant market position within the specialized healthcare real estate niche, supported by a substantial asset base relative to its lean employee count, suggesting high operational leverage and capital intensity typical of the REIT structure.
財務健全性
The company reported a trailing twelve-month revenue of $379.29M with a net income of $141.98M and EBITDA of $276.77M. The substantial gap between the $379.29M revenue and $141.98M net income reveals a robust cost structure where operating expenses, including interest and taxes, consume approximately 62.8% of total revenue before arriving at net profit. Free cash flow stands at $195.47M, indicating strong financial flexibility that allows the company to service its obligations, fund acquisitions, or return capital without relying heavily on external financing. Margins are highly favorable, with a gross margin of 81.0%, an operating margin of 61.3%, and a profit margin of 37.5%, reflecting the asset-light nature of the sale-leaseback business model where revenue is primarily derived from financing fees rather than property management fees alone. Liquidity and leverage metrics show a cash position of $113.38M against total debt of $1.52B, resulting in a debt-to-equity ratio of 97.57%, which signifies a highly leveraged balance sheet common for REITs but requiring careful monitoring of refinancing risks. The current ratio is 0.54, indicating that current assets are less than half of current liabilities, suggesting limited short-term liquidity and a reliance on long-term financing or asset sales to meet immediate obligations. Return on equity is 9.6% and return on assets is 4.5%, metrics that reveal moderate management effectiveness in generating returns on the substantial capital invested in healthcare assets, particularly when weighed against the high leverage levels.
バリュエーション評価
Valuation multiples show a trailing P/E ratio of 28.51 and a forward P/E of 23.66, implying that the market expects earnings to grow or stabilize in the future to justify the lower forward multiple relative to current earnings. The price-to-book ratio is 2.55, indicating that the market prices the company at a significant premium over its net asset book value, reflecting the value of its land, buildings, and favorable lease terms. Alternative valuation metrics include a price-to-sales ratio of 11.00 and an EV/EBITDA of 20.19, suggesting that investors are willing to pay a high multiple for sales given the recurring revenue nature of sale-leaseback agreements. Price action over the last year ranges between a 52-week high of $91.38 and a 52-week low of $66.41, with the current price position dependent on real-time market data but historically trading within this defined volatility range. The stock exhibits a beta of 0.66, meaning its price volatility is roughly 34% lower than the broader market, offering a relative defensive characteristic often sought in healthcare real estate portfolios during periods of market uncertainty.
Growth & Income
Recent performance data indicates a revenue growth rate of -2.6% year-over-year and an earnings growth rate of -43.0% year-over-year. Earnings are growing significantly slower than revenue in this context, as negative earnings growth far exceeds negative revenue growth, implying that cost pressures or one-time charges may be impacting profitability more severely than top-line contraction. As a dividend payer, the company offers a dividend yield of 4.2% with a payout ratio of 120.5%, indicating that the dividend is not fully covered by current earnings and relies on cash flow or capital reserves, which raises questions regarding the immediate sustainability of the payout without earnings recovery. Given the negative earnings growth and payout ratio exceeding 100%, the company is not currently reinvesting earnings into growth but rather distributing capital that exceeds reported net income, a strategy that must be balanced against the high debt load and declining earnings trajectory. Overall, the growth and income profile presents a high-yield opportunity tempered by recent contraction in profitability and a payout ratio that exceeds earnings capacity.